Last reviewed · How we verify
GSK3858279 IV — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK3858279 IV (GSK3858279 IV) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK3858279 IV TARGET | GSK3858279 IV | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK3858279 IV CI watch — RSS
- GSK3858279 IV CI watch — Atom
- GSK3858279 IV CI watch — JSON
- GSK3858279 IV alone — RSS
Cite this brief
Drug Landscape (2026). GSK3858279 IV — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk3858279-iv. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab